Eyal S. Ron will be representing AmacaThera at PODD: Partnership Opportunities in Drug Delivery Conference in Boston on October 28th and 29th. Please reach out to Eyal if you will be attending and would like to learn more about the delivery power of our AmacaGel™ platform. #drugdelivery #partnerships #PODD
I’m excited to represent AmacaThera at the 14th annual PODD: Partnership Opportunities in Drug Delivery Community News in Boston on October 28 and 29 (https://lnkd.in/e5xpGnjN). Our AmacaGel™ platform enables cost-effective, long-acting therapies with proven clinical validation, ideal for localized or subcutaneous sustained drug delivery, improving patient outcomes across multiple therapeutic areas. Our lead drug candidate, AMT-143, is an opioid-free formulation for the sustained release of an anesthetic. It offers significant benefits to patients, doctors, and healthcare stakeholders concerned about the risks of addictive medications. Without altering current surgical practices, AMT-143 is locally administered at the time of surgery and calibrated to provide sustained post-operative pain control, helping patients through their recovery period. #AmacaThera #PODD2024 #DrugDelivery #SustainedRelease #OpioidFree #HealthcareInnovation #PainManagement #Biotechnology #Pharma #Boston #HealthcareSolutions .